These molecules demonstrate stronger antiproliferative capabilities and broader applicability compared with traditional MDM2 inhibitors by restoring p53 stability and activating its downstream apoptotic pathways, particularly showing potential in p53‐dependent tumors such as malignant melanoma and soft tissue sarcomas. This evidence concerns the gene TP53 and melanoma.